Screening for Fabry disease in high-risk populations: A systematic review

Journal of Medical Genetics

Volumn 47, Issue 4, 2010, Pages 217-222

  Linthorst, G E ^a   Bouwman, M G ^a   Wijburg, F A ^a   Aerts, J M F G ^a   Poorthuis, B J H M ^a   Hollak, C E M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; DNA;

COHORT ANALYSIS; DATA BASE; DIALYSIS; EMBASE; FABRY DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; KIDNEY TRANSPLANTATION; MEDLINE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCREENING; SYSTEMATIC REVIEW;

ALPHA-GALACTOSIDASE; DIALYSIS; FABRY DISEASE; FEMALE; HUMANS; MALE; MASS SCREENING; PREVALENCE;

EID: 77951546978     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2009.072116     Document Type: Review

References (55)

1. Kint JA. Fabry's disease: alpha-galactosidase deficiency. Science 1970;167:1268-1269
2. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-1167
3. Desnick RJ, Ioannou YA, Eng ME. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds The metabolic and molecular bases of inherited disease 8th edn 3 New York: McGraw-Hill 2001:3733-3774
4. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Kral V, Dorazilova V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990;417:449-455
5. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64:801-807
6. Verovnik F, Benko D, Vujkovac B, Linthorst GE. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet 2004;12:678-681 (Pubitemid 39172431)
7. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-128
8. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775 (Pubitemid 33032933)
9. Mehta A, Ricci R, Widmer U, Dehout F, Garcia dL, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242
10. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16. (Pubitemid 32634266)
11. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74. (Pubitemid 38756338)
12. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-2749 (Pubitemid 32525371)
13. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86. (Pubitemid 351640010)
14. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-1557 (Pubitemid 46717522)
15. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-156 (Pubitemid 29396979)
16. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida, Kuriyama M, Hayashibe H, Sakuraba H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293
17. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40. (Pubitemid 43927374)
18. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G→A (IVS4+919G→A). Hum Mutat 2009;30:1397-1405
19. Hauser AC, Lorenz M, Voigtlander T, Fodinger M, Sunder-Plassmann G. Results of an ophthalmologic screening programme for identification of cases with Anderson-Fabry disease. Ophthalmologica 2004;218:207-209 (Pubitemid 38596588)
20. Vedder AC, Gerdes VE, Poorthuis BJ, Helmond M, Trip MD, Aerts JM, Hollak CE. Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males. J Inherit Metab Dis 2007;30:988.
21. Walters BAJ, Prichard M, McCardle H, et al. Prevalence of reduced plasma a-Galactosidase activity in a cohort of male patients on hemodialysis (HO) in the United States. Abstract, Annual Clinical Genetics Meeting, of the American College of Medical Genetics, March 2002, New Orleans, USA.
22. Spada M, Pagliardini S. Screening for Fabry disease in end-stage nephropathies. J Inherit Metab Dis 2002;25(Suppl I):113.
23. Linthorst GE, Hollak CE, Korevaar JC, van Manen JG, Aerts JM, Boeschoten EW. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003;18:1581-1584
24. Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 2005;9:228-232 (Pubitemid 41414122)
25. Maslauskiene R, Bumblyte IA, Sileikiene E, Grazulis S, Laurinavicius A, Pleckaitis M, Alekniene D, Dobrovolskiene R, Vainauskas V, Juodeikiene L, Steckis R, Sakalauskiene M, Macius K, Urbanaviciene J, Labutiene V, Gaupsiene E, Ziaukiene G, Burbaickaja S, Gailiunas J. [The prevalence of Fabry's disease among male patients on hemodialysis in Lithuania (a screening study)] (In Lithuanian.). Medicina (Kaunas) 2007;43(Suppl 1):77-80.
26. Andrade J, Waters PJ, Singh RS, Levin A, Toh BC, Vallance HD, Sirrs S. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 2008;3:139-145
27. Porsch DB, Nunes AC, Milani V, Rossato LB, Mattos CB, Tsao M, Netto C, Burin M, Pereira F, Matte U, Giugliani R, Barros EJ. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report. Ren Fail 2008;30:825-830
28. Kleinert J, Kotanko P, Spada M, Pagliardini S, Paschke E, Paul K, Voigtlander T, Wallner M, Kramar R, Stummvoll HK, Schwarz C, Horn S, Holzer H, Fodinger M, Sunder-Plassmann G. Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 2009;22:287-292
29. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-1411 (Pubitemid 34263268)
30. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110:1047-1053 (Pubitemid 39319001)
31. Utsumi K, Kase R, Takata T, Sakuraba H, Matsui N, Saito H, Nakamura T, Kawabe M, Iino Y, Katayama Y. Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol 2000;4:49-51. (Pubitemid 30243385)
32. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Fodinger M, Sunder-Plassmann G. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004;15:1323-1329 (Pubitemid 38526014)
33. Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, Choukroun G, Unwin R, Jaeger P. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 2005;101:c33-c8. (Pubitemid 41159942)
34. Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, Kuwahara K, Nakano T, Yasumoto N, Nonoguchi H, Tomita K. Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 2005;64:281-287 (Pubitemid 41448430)
35. Merta M, Reiterova J, Ledvinova J, Poupetova H, Dobrovolny R, Rysava R, Maixnerova D, Bultas J, Motan J, Slivkova J, Sobotova D, Smrzova J, Tesar V. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 2007;22:179-186 (Pubitemid 46050343)
36. Terryn W, Poppe B, Wuyts B, Claes K, Maes B, Verbeelen D, Vanholder R, De Boeck K, Lameire N, De Paepe A, De Schoenmakere G. Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrol Dial Transplant 2008;23:294-300. (Pubitemid 351767362)
37. De Schoenmakere G, Poppe B, Wuyts B, Claes K, Cassiman D, Maes B, Verbeelen D, Vanholder R, Kuypers DR, Lameire N, De Paepe A, Terryn W. Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrol Dial Transplant 2008;23:4044-4048
38. Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I, Fernandez X, de NR, de la MG, Paya E, Yague J, Egido J. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007;50:2399-2403 (Pubitemid 50011583)
39. Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Lohr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794-1796 (Pubitemid 41642643)
40. Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, Mehta A, Timmerman T, Vincent MF, De Deyn PP. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 2007;109:479-484
41. Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan J. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 2002;70:994-1002. (Pubitemid 34259315)
42. Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry's disease: data fromthe Fabry Outcome Survey. Br J Ophthalmol 2007;91:210-214 (Pubitemid 46202871)
43. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973;81:157-171
44. Rietra PJ, Tager JM, De Groot WP. Detection of Fabry hemizygotes and heterozygotes by measurement of -galactosidase in urine. Clin Chim Acta 1972;40:229-235
45. Linthorst GE, Poorthuis BJ, Hollak CE. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol 2008;51:2082; [author reply -3].
46. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 2005;353:201-203
47. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007;30:68-78. (Pubitemid 46140228)
48. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 2003;80:307-314 (Pubitemid 37324717)
49. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008;105:2812-2817 (Pubitemid 351723626)
50. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of {alpha}-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 2004;50:1979-1985.
51. Fuller M, Sharp PC, Rozaklis T, Whitfield PD, Blacklock D, Hopwood JJ, Meikle PJ. Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin Chem 2005;51:688-694 (Pubitemid 40463920)
52. Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Mills K, Winchester B, Keutzer J. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab 2005;85:196-202. (Pubitemid 40840759)
53. Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melancon SB, Stockley T, Clarke JT, Drouin R. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 2008;93:331-340 (Pubitemid 351192345)
54. Barr C, Clarke JT, Ntwari A, Drouin R, Auray-Blais C. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months. Mol Genet Metab 2009;97:278-283
55. Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Odaka H, Owada M. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol 2008;23:1461-1471